Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Effect of rituximab on human in vivo antibody immune responses.

Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A; Type 1 Diabetes TrialNet Study Group.

J Allergy Clin Immunol. 2011 Dec;128(6):1295-1302.e5. doi: 10.1016/j.jaci.2011.08.008. Epub 2011 Sep 9.

2.

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A.

Arthritis Rheum. 2010 Jan;62(1):64-74. doi: 10.1002/art.25034.

3.

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

N Engl J Med. 2009 Nov 26;361(22):2143-52. doi: 10.1056/NEJMoa0904452.

4.

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, Young M, Pescovitz MD.

Am J Transplant. 2005 Jan;5(1):50-7.

5.

Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab.

Herrera D, Rojas OL, Duarte-Rey C, Mantilla RD, Angel J, Franco MA.

PLoS One. 2014 May 12;9(5):e97087. doi: 10.1371/journal.pone.0097087. eCollection 2014.

6.

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, Malmström V, Trollmo C.

Clin Immunol. 2007 Jan;122(1):62-74. Epub 2006 Oct 13.

PMID:
17046329
7.

Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.

Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

J Immunol. 2011 Aug 15;187(4):1998-2005. doi: 10.4049/jimmunol.1100539. Epub 2011 Jul 20.

8.

Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia.

Ercan TE, Soycan LY, Apak H, Celkan T, Ozkan A, Akdenizli E, Kasapçopur O, Yildiz I.

J Pediatr Hematol Oncol. 2005 May;27(5):273-7.

PMID:
15891564
9.

Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.

Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W.

J Invest Dermatol. 2008 Nov;128(11):2615-24. doi: 10.1038/jid.2008.98. Epub 2008 May 22.

10.

Humoral immune response after post-chemotherapy booster diphtheria-tetanus-pertussis vaccine in pediatric oncology patients.

Cheng FW, Leung TF, Chan PK, Lee V, Shing MK, Chik KW, Yuen PM, Li CK.

Pediatr Blood Cancer. 2009 Feb;52(2):248-53. doi: 10.1002/pbc.21792.

PMID:
18937325
11.

Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.

Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O.

PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.

12.

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH.

Arch Neurol. 2010 Jun;67(6):707-14. doi: 10.1001/archneurol.2010.99.

13.

A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.

Kamburova EG, Koenen HJ, Borgman KJ, ten Berge IJ, Joosten I, Hilbrands LB.

Am J Transplant. 2013 Jun;13(6):1503-11. doi: 10.1111/ajt.12220. Epub 2013 Apr 9.

14.

In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.

Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I.

Am J Transplant. 2012 Feb;12(2):341-50. doi: 10.1111/j.1600-6143.2011.03833.x. Epub 2011 Nov 9.

15.

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, Yang GX, Nakatani T, Vierling J, Lindor K, Gershwin ME, Bowlus CL.

Hepatology. 2012 Feb;55(2):512-21. doi: 10.1002/hep.24748.

PMID:
22006563
16.

Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.

Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):16-8.

17.

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.

Fluge Ø, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O, Mella O.

PLoS One. 2015 Jul 1;10(7):e0129898. doi: 10.1371/journal.pone.0129898. eCollection 2015.

18.

B-lymphocyte depletion with rituximab and β-cell function: two-year results.

Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

Diabetes Care. 2014 Feb;37(2):453-9. doi: 10.2337/dc13-0626. Epub 2013 Sep 11.

19.

Rituximab as monotherapy for elicited xenoreactive antibody responses.

Gonzalez-Stawinski GV, Davis RD Jr.

J Heart Lung Transplant. 2006 Dec;25(12):1462-6. Epub 2006 Oct 30.

PMID:
17178342
20.

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA.

J Neuroimmunol. 2006 Nov;180(1-2):63-70. Epub 2006 Aug 14.

Supplemental Content

Support Center